New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatm...(of people living with HIV/AIDS and focus...),Health

Date:11/27/2007

of people living with HIV/AIDS, and focusing on specific, measurable outcomes," said Dr. Jim Yong Kim, Director of the Francois-Xavier Bagnoud Center for Health and Human Rights (FXB) at Harvard University. "We must learn from and build on these foundations because they represent the best chance we've ever had to build comprehensive health systems in the poorest settings."

"It is irresponsible to get bogged down in debates on simplistic dichotomies like prevention versus treatment or disease-specific funding versus strong health systems. We can, and we must, do all of this, better, for more people, and in an increasingly coherent way," added Chris Collins, a coordinator of the project.

"The UNAIDS epidemiologic estimates released last week show that we're getting closer to reaching the goal of treatment for all," said Shona Schonning of the Russia research team. "The UNAIDS report shows that prevention and treatment programming have had impact. Now its time to scale up these programs and continue to make progress on what remains a devastating epidemic."

In the report, civil society advocates in 14 countries identify specific problems and recommend solutions to improve AIDS drug access:

-- In Argentina, high cost and restrictions on some drugs impede access to some second line and other medicines.

-- In Belize, human resources shortfalls, price increases and inadequate quality assurance hamper drug delivery.

-- In Cambodia, expanded access to drug resistance and viral load testing is needed, as is increased attention to drug quality.

-- In China, access to second-line therapy is extremely limited, new WHO treatment guidelines on improved first-line treatment have not been widely implemented and patents on key medicines are preventing cost-cutting generic competition.

-- In the Dominican Republic, new intellectual property laws and patent enforcement by Merck are leading to higher prices and limited acces
'/>"/>

SOURCE International Treatment Preparedness Coalition Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin